tion. The solid dots, open circles and triangles represent the beginning, mid-point and end of study values respectively. There is an apparent tendency or trend for the mean values to progressively decline during the study in the Thllffia group, suggesting the development of resistance. However, when these data are subjected to paired t-testing, a statistical manipulation which tends to find signi6cance in even small deviations, statistical s i g dcanoe is not shown. I believe it is important that we, as scientists, insist upon statistical signi6cance to m s i d e r a hrpothesis proven rather than accepting trends which may be misleading. Moreover, there remains an important distinction between scientific signi6caoce and clinical sigdcance. Even if we had demonstrated statistical signi6cance. I doubt that a loss of responsiveness by only a few milliliters of FEV, is signi6cant to the health of the patient. The ephedrine group showed a greater variance. The super6cial trend is hyporesponsiveness at six weeks with a tendency for improved nqonsiveners at three month. The only statistically sigdcant points on this graph are the six-week values at four, five and six hours (P < .05). With ephedrine, the magnitude of the merences in means suggests the possibility of clinical significance. If one considers only the best FEV, achieved on test days at the end and beginning of the study, 18 subjects had a lower FEV, and ten a higher FEV,. Possibly some patients develop tolerance, and others do not.
tion. The solid dots, open circles and triangles represent the beginning, mid-point and end of study values respectively. There is an apparent tendency or trend for the mean values to progressively decline during the study in the Thllffia group, suggesting the development of resistance. However, when these data are subjected to paired t-testing, a statistical manipulation which tends to find signi6cance in even small deviations, statistical s i g dcanoe is not shown. I believe it is important that we, as scientists, insist upon statistical signi6cance to m s i d e r a hrpothesis proven rather than accepting trends which may be misleading. Moreover, there remains an important distinction between scientific signi6caoce and clinical sigdcance. Even if we had demonstrated statistical signi6cance. I doubt that a loss of responsiveness by only a few milliliters of FEV, is signi6cant to the health of the patient. The ephedrine group showed a greater variance. The super6cial trend is hyporesponsiveness at six weeks with a tendency for improved nqonsiveners at three month. The only statistically sigdcant points on this graph are the six-week values at four, five and six hours (P < .05). With ephedrine, the magnitude of the merences in means suggests the possibility of clinical significance. If one considers only the best FEV, achieved on test days at the end and beginning of the study, 18 subjects had a lower FEV, and ten a higher FEV,. Possibly some patients develop tolerance, and others do not. Figure 2 represents our study in progress with at present only h e subjects in each group. The total duration of this study is six weeks rather than three months, and Tbllffia is compared to terbutaline. With such small numbers of patients in this preliminary examination of the data, I am hesitant to make any interpretations except perhaps that both Thllffia and terbutaline retain an apparent bronchodilator action of unspecified degree after six weeh of continuous administration three or four times daily.
In summary, our studies largely hint at the develop ment of mild tolerance to beta agonists which is likely of little consequence in practical patient management.
The Development of Drug Tolerance
During Long-term Beta2-Agonist Bronchodilator Therapy
n a series of double-blind studies we have conducted
.
lnvolvlng many of the newer beta, adrenergic drugs, a fairly consistent pattern has emerged ivhich indicates that repetitive doses of these drugs will result in only a relatively minor decrease in their initial effect, but a relatively marked decrease in the duration of effect.
In a study comparing metaproterenol and isopr* terenol over a twl~month period the percentage of improvement in FEV, noted on day 1 of the trial was almost matched on day 80, but the four-hour duration noted on day 1 decreased to less than three hours on day 80. The patient on isoproterenol fared even worse; the initial effect on day 80 was markedly diminished from that m day 1 and the duration was less than an hour. In another study in 28 asthmatic patients utilizing 5 percent metaproterenol solution in a hand-bulb nebulizer and using a relatively large dose of ten sprays four times a day for a W a y period, it was noted at the conclusion of the study that there was stiU a g o d response to metaproterenol but the duration of response was less than at the start of the study.
In a similar study using metaproterenol solution administered by IPPB three to four times a day over a 90-day period persistence of the initial response was noted on day 90, but the duration again was markedly decreased (Fig 1 ) .
In a study of 33 asthmatic patients comparing ephedrine tablets and metaproterenol tablets over a W d a y period, there was a marked trend toward a decrease in both initial response and duration of response to metaproterenol after 80 days. This study was done as a double-blind cross-over test, but when we analyzed the data, we found that the baselines had changed so that it was impossible to evaluate the crossover data with any statistical significance. An interesting point was noted, however. Although response to ephedrine was poor in the initial group studied, the group on metapr* terenol for 80 days and then placed on ephedrine showed an excellent response to ephedrine. This response was lost, however, when tested at 30 and 80 days.
This would seem to indicate that effects other than refractoriness of beta-adrenergic receptors was involved as these patients had been on metaproterenol with only a three-day washout period before they were placed on ephedrine.
To confuse us further, a study of metaproterenol syrup in a pediahic population showed an excellent duration Of great interest is our most recent study c o m m g the effectiveness of terbutaline and feooteml tablets. In this instance, over a 42-day period, there was no apparent decrease in either initial effect or duration of effectiveness with either drug (Fig 2) . This would indicate that the mode of a-t i on may be of considerable sigruficance and the larger side chains which characterize the con6guration of these drugs sigdcantly decrease the rate of metabolism by body enzymes and/or their ability to be bound by albumin.
The whole question of drug refractoriness may be academic as far as clinical utilization of these drugs is concerned. In a multifaceted disease such as asthma it is naive to expect complete control through stimulation of beta-adrenergic receptors. Most likely there are multiple mechanisms which result in the decreased bene6t frequently seen with these drugs after prolonged use. In most cases, this is due more to a change in the patient's disease than to diminished effectiveness of the drug. were used duriog the month preceding the study. AU testing was done at the same time of day. The age, race, sex, and physician's impression of the severity of the asthma was not significantly a e r e n t in the two groups. Duration of asthma for those receiving fenoterol MDI was 18 yean and was 15 years for the isoproterenol group. During the 90-day treatment period, one subject receiving fenoterol used one aminophylline supposito~y and five received daily prednisone. Among those receiving isoproterenol, one subject required one dose of intramuscular epinephrine and three received prednisone. Cromolyn was used throughout the pretreatment and treatment period by one person receiving fenoterol. 
Efficacy and Side Effects of Fenoterol

